EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Early Weight Regain After GLP ‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

M A Damhof iD, F H van Bruggen iD, E N van Roon

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von M A Damhof und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, Frisius Medical Center, Leeuwarden, the Netherlands. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Weight Gain, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment effects and optimal strategies for treatment withdrawal. Recent systematic reviews and meta‐analyses consistently demonstrate that weight regain after GLP‐1RA discontinuation is substantial and follows a characteristic trajectory, with a large proportion occurring during the early post‐cessation period. This front‐loaded pattern suggests that the initial months after treatment cessation represent a critical window influencing long‐term outcomes. Mechanistically, post‐cessation weight regain appears to reflect the interaction of multiple processes. These include restoration of appetite following withdrawal of pharmacological GLP‐1 signalling, compensatory increases in orexigenic hormones such as ghrelin, alterations in incretin balance including glucose‐dependent insulinotropic polypeptide (GIP) and potential adaptive changes in GLP‐1 receptor signalling pathways during prolonged pharmacological exposure, although evidence for a direct role in post‐cessation weight regain remains limited. These converging mechanisms have important clinical implications, as abrupt discontinuation may result in a transient mismatch between increased biological drive for weight regain and the sudden loss of pharmacological appetite suppression. In this context, strategies aimed at mitigating early weight regain are of increasing interest. Recent randomised evidence suggests that reduced‐intensity pharmacological maintenance may attenuate weight regain compared with abrupt discontinuation. However, whether structured tapering strategies can successfully facilitate treatment discontinuation remains unknown and requires prospective evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsWeight GainObesityHypoglycemic AgentsHumansGlucagon-Like Peptide-1 ReceptorTreatment InterruptionSignal TransductionWeight LossIncretins

Stichwörter der Autor:innen

GLP‐1 receptor agonistsobesitytreatment de‐escalationweight regainweight‐loss maintenance

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorIncretinsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, Frisius Medical Center, Leeuwarden, the Netherlands.
  • Department of Primary and Long-Term Care, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

ORCID-Profile: M A Damhof, F H van Bruggen

Zitieren

APA

Damhof, M. A., van Bruggen, F. H., & van Roon, E. N. (2026). Early Weight Regain After GLP ‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71075

Vancouver

Damhof MA, van Bruggen FH, van Roon EN. Early Weight Regain After GLP ‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71075

BibTeX
@article{Damhof2026,
  author = {Damhof, M A and van Bruggen, F H and van Roon, E N},
  title = {Early Weight Regain After GLP ‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71075}
}
Kostenlos starten →